Table 1. Effect of oral paclitaxel (Liporaxel®) and intravenous paclitaxel (Taxol®) on antioxidant activities in rat.
|
|
Sample name |
NC |
LPX |
TAX |
|
|
Serum (nmol/ml) |
15.68±1.22 |
19.75±0.81*** |
23.49±0.63***### |
|
|
Sciatic nerve (nmol/mg prot) |
0.18±0.01 |
0.14±0.01** |
0.16±0.01***### |
|
MDA |
DRG L5 (nmol/mg prot) |
0.12±0.02 |
0.15±0.02 |
0.18±0.05** |
|
|
DRG L6 (nmol/mg prot) |
0.11±0.01 |
0.12±0.01** |
0.14±0.01**### |
|
|
Serum (inhibition %) |
82.09±10.49 |
64.37±6.25** |
55.78±8.21*** |
|
SOD activity |
Sciatic nerve (inhibition, %) |
86.98±7.60 |
68.679±8.31*** |
46.89±9.91***### |
|
|
DRG L5 (inhibition, %) |
81.89±4.96 |
62.74±10.41** |
51.42±15.22*** |
|
|
DRG L6 (inhibition, %) |
78.77±13.79 |
54.06±12.33** |
43.02±12.87*** |
|
|
Serum (mU/mL) |
3.64±1.35 |
2.37±0.74* |
1.66±0.75** |
|
Gpx activity |
Sciatic nerve (mU /mg prot) |
3.61±0.90 |
2.42±0.46** |
1.97±0.54*** |
|
|
DRG L5 (mU /mg prot) |
6.72±1.12 |
2.89±1.50*** |
1.60±0.81*** |
|
|
DRG L6 (mU /mg prot) |
5.87±1.17 |
3.04±1.57*** |
1.52±1.06***# |
|
|
Serum (% to NC) |
100.00±14.66 |
75.94±10.16*** |
59.19±14.54***## |
|
GSH |
Sciatic nerve (% to NC) |
100.03±3.90 |
76.86±4.43*** |
70.01±3.00***## |
|
|
DRG L5 (% to NC) |
100.00±7.83 |
85.84±7.86** |
70.18±5.99***### |
|
|
DRG L6 (% to NC) |
100.00±13.91 |
70.99±7.47*** |
58.332±4.34***# |
NC, normal control; LPX, Liporaxel® treated group; TAX, Taxol® treated group. MDA, malondialdehyde (Lipid peroxidation); SOD, superoxide dismutase; Gpx, glutathione peroxidase; GSH, total glutathione; DRG, dorsal root ganglion. The data are reported as the mean ±SEM (n = 10). *, p< 0.05; **, p< 0.01; ***, p< 0.001, Bonferronipost hoc test following one-way ANOVA versus the NC group. #, p< 0.05; ##, p< 0.01 and ###, p< 0.001, Bonferronipost hoc test following one-way ANOVA versus the LPX group.